650 related articles for article (PubMed ID: 26414730)
21. Improving cardiovascular and renal outcomes in gout: what should we target?
Richette P; Perez-Ruiz F; Doherty M; Jansen TL; Nuki G; Pascual E; Punzi L; So AK; Bardin T
Nat Rev Rheumatol; 2014 Nov; 10(11):654-61. PubMed ID: 25136785
[TBL] [Abstract][Full Text] [Related]
22. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
23. Expert opinion on emerging urate-lowering therapies.
Stamp LK; Merriman TR; Singh JA
Expert Opin Emerg Drugs; 2018 Sep; 23(3):201-209. PubMed ID: 30244605
[TBL] [Abstract][Full Text] [Related]
24. [Therapy of hyperuricemia and gout].
Pöllmann G; Kullich W; Klein G
Wien Med Wochenschr; 1997; 147(16):382-7. PubMed ID: 9446417
[TBL] [Abstract][Full Text] [Related]
25. Gout treatment: should we aim for rapid crystal dissolution?
Pascual E; Andrés M; Vela P
Ann Rheum Dis; 2013 May; 72(5):635-7. PubMed ID: 23322814
[TBL] [Abstract][Full Text] [Related]
26. Hyperuricaemia and gout.
Shipley M
J R Coll Physicians Edinb; 2011 Sep; 41(3):229-33. PubMed ID: 21949921
[TBL] [Abstract][Full Text] [Related]
27. Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure.
Borghi C; Palazzuoli A; Landolfo M; Cosentino E
Heart Fail Rev; 2020 Jan; 25(1):43-51. PubMed ID: 31745840
[TBL] [Abstract][Full Text] [Related]
28. Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data.
Koto R; Nakajima A; Horiuchi H; Yamanaka H
Pharmacoepidemiol Drug Saf; 2021 Feb; 30(2):157-168. PubMed ID: 32939919
[TBL] [Abstract][Full Text] [Related]
29. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
Paschos P; Athyros VG; Tsimperidis A; Katsoula A; Grammatikos N; Giouleme O
Curr Vasc Pharmacol; 2018; 16(3):269-275. PubMed ID: 28676018
[TBL] [Abstract][Full Text] [Related]
30. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
31. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
Goldfarb DS; MacDonald PA; Hunt B; Gunawardhana L
J Rheumatol; 2011 Jul; 38(7):1385-9. PubMed ID: 21572152
[TBL] [Abstract][Full Text] [Related]
32. Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension.
Juraschek SP; Appel LJ; Miller ER
Am J Hypertens; 2017 Sep; 30(9):871-875. PubMed ID: 28830083
[TBL] [Abstract][Full Text] [Related]
33. [Hyperuricemia].
Chizyński K; Rózycka M
Pol Merkur Lekarski; 2005 Nov; 19(113):693-6. PubMed ID: 16498814
[TBL] [Abstract][Full Text] [Related]
34. A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
Perez-Ruiz F; Herrero-Beites AM; Carmona L
Arthritis Rheum; 2011 Dec; 63(12):4002-6. PubMed ID: 21898351
[TBL] [Abstract][Full Text] [Related]
35. GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
Torres RJ; Puig JG
Int J Rheum Dis; 2018 Jun; 21(6):1270-1276. PubMed ID: 29879316
[TBL] [Abstract][Full Text] [Related]
36. [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].
Fujimori S
Nihon Rinsho; 2008 Apr; 66(4):729-35. PubMed ID: 18409523
[TBL] [Abstract][Full Text] [Related]
37. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
[TBL] [Abstract][Full Text] [Related]
38. Hyperuricemia, the kidneys, and the spectrum of associated diseases: a narrative review.
Jalal DI
Curr Med Res Opin; 2016 Nov; 32(11):1863-1869. PubMed ID: 27470664
[TBL] [Abstract][Full Text] [Related]
39. Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL?
Ruoff G; Edwards NL
Postgrad Med; 2016 Sep; 128(7):706-15. PubMed ID: 27558643
[TBL] [Abstract][Full Text] [Related]
40. Febuxostat--treatment for hyperuricemia and gout?
Moreland LW
N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
